Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
Google Secures Pentagon AI Deal for Classified Projects 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
CANTON, Mass., April 20, 2017 -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that it will present at the 42nd Annual Deutsche Bank Healthcare Conference in Boston. The presentation will take place at 10:40 a.m. ET on Wednesday, May 3, 2017 at the InterContinental Boston Hotel.
About Collegium Pharmaceutical, Inc.
Collegium is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its proprietary DETERx® technology platform for the treatment of chronic pain and other diseases. The DETERx technology platform is designed to provide extended-release delivery, unique abuse-deterrent properties, and flexible dose administration options.
About Xtampza ER
Xtampza® ER is Collegium’s first product utilizing the DETERx technology platform. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
Contact: Alex Dasalla [email protected]
